Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other idiopathic pain conditions, announced the closing of its Series C funding round, with a first closing of $45 million.

Philadelphia-based New Rhein Healthcare Investors led the round, with wide participation of existing investors aMoon, Lightspeed Venture Partners, LionBird, Takoa Invest, and Corundum Open Innovation.